

**DEPARTMENT OF JUSTICE****Antitrust Division****Notice Pursuant to the National Cooperative Research and Production Act of 1993—Cooperative Research Group Corrosion Under Insulation—Phase 2 (CUI—Phase 2)**

Notice is hereby given that, on January 6, 2025, pursuant to section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* (“the Act”), Cooperative Research Group Corrosion Under Insulation—Phase 2 (CUI—Phase 2) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing (1) the identities of the parties to the venture and (2) the nature and objectives of the venture. The notifications were filed for the purpose of invoking the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances.

Pursuant to section 6(b) of the Act, the identities of the parties to the venture are: Conoco Phillips Company, Houston, TX; Nanotech Inc., Houston, TX; Armancell Engineered Systems Ltd., London, UNITED KINGDOM; The Sherwin Williams Company, Cleveland, OH; PPG Industries, Incorporated, Pittsburgh, PA; International Paint LLC, Houston, TX; Superior Products International II, Inc., Shawnee, KS; Promat Incorporated, Maryville, TN; Jotun A/S, Sandefjord, KINGDOM OF NORWAY; Hempel A/S, Lyngby, KINGDOM OF DENMARK; BP America Production Company, Houston, TX; Air Products and Chemicals, Inc., Allentown, PA; Aspen Aerogels, Inc., Marlborough, MA; Exxonmobil Technology and Engineering, Spring, TX; and Equinor Energy AS, Stavanger, KINGDOM OF NORWAY. The general area of CUI—Phase 2’s planned activities are to test the performance of protective coating and insulation products including insulative coatings using the TM21442 test method and a variant of that approach. In addition to the laboratory and field activities, Phase 2 CUI JIP will be used to test, in laboratory setups, promising CUI sensing technologies suitable for CUI monitoring. These preliminary tests will investigate and compare the performance of a range of CUI sensors using the test methodologies proposed above. The CUI Phase 2 JIP shall focus on four primary technical tasks as follows: performance testing of CUI Protective Coating/Insulation Systems;

performance evaluation of CUI Insulative Coatings; performance evaluation of CUI Insulative Coatings; and preliminary evaluation of CUI Sensors.

**Suzanne Morris,**

*Deputy Director Civil Enforcement Operations, Antitrust Division.*

[FR Doc. 2025–10815 Filed 6–12–25; 8:45 am]

**BILLING CODE P**

**DEPARTMENT OF JUSTICE****Antitrust Division****Notice Pursuant to the National Cooperative Research and Production Act of 1993—Rapid Response Partnership Vehicle**

Notice is hereby given that, on April 8, 2025, pursuant to section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* (“the Act”), Rapid Response Partnership Vehicle (“RRPV”) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances.

Specifically, Fisher BioServices, Inc., Rockville, MD; Landmark Vaccines, Ltd., Loughborough, UNITED KINGDOM; Rx Bandz, Locust Valley, NY; Zeteo Tech, Inc., Sykesville, MD; BioNet-Asia Co., Ltd, Bangkok, KINGDOM OF THAILAND; EmitBio, Inc., Morrisville, NC; Matisse Pharmaceuticals, B.V., Geleen, KINGDOM OF THE NETHERLANDS; National Institute for Pharmaceutical Technology and Education, Inc., Minneapolis, MN; ProtonDx, Ltd., London, UNITED KINGDOM; BioVaxys Technology Corp., Etobicoke, CANADA; Enplas, Santa Clara, CA; RHEAVITA BV, Ghent, KINGDOM OF BELGIUM; Celltheon, Union City, CA; Chromatan, Inc., Lower Gwynedd, PA; Cyrus Biotechnology, Seattle, WA; Eradivir, Inc., West Lafayette, IN; InDevR, Inc., Boulder, CO; Kudo Biotechnology, Inc., Needham, MA; Panoplia Laboratories, Inc., Cambridge, MA; The Regents of the University of California on behalf of its Los Angeles campus, Los Angeles, CA; Meridian Medical Technologies LLC, St. Louis, MO; Sarfez Pharmaceuticals, Inc., Vienna, VA; Tiba Biotech LLC, Cambridge, MA; Ecolab, Inc., Philadelphia, PA; Unicorn Biotechnologies, Inc., Newark, NJ;

Zipcode Bio, Weston, MA; Acclinate, Inc., Birmingham, AL; Klim-Loc Medical, Inc., Carbondale, CO; Primary Diagnostics, Inc. dba Primary.Health, San Francisco, CA; Epitogenesis, Inc., Virginia Beach, VA; Microbio, Ltd., Brisbane, COMMONWEALTH OF AUSTRALIA; Aldevron LLC, Fargo, ND; BC3 Technologies, Inc., Baltimore, MD; Genvax, Ames, IA; Maxim Biomedical, Inc., Rockville, MD; Piezo Therapeutics, Inc., Atlanta, GA; Virtu, Inc., Leesburg, VA; Digital Infuzion LLC, Rockville, MD; Neolixir, Ltd., Perth, AUSTRALIA; XCMR, Inc., Narberth, PA; GenevationUS LLP, Sacramento, CA; Respana Therapeutics, Inc., Philadelphia, PA; University of Louisiana at Lafayette, Lafayette, LA; EriVan, Alachua, FL; President and Fellows of Harvard College, Cambridge, MA; MedinCell, Inc., Jacou, FRENCH REPUBLIC; Ambient Biosciences, Ann Arbor, MI; Antirna, Inc., Burlington, MA; Avid Bioservices, Inc., Tustin, CA; CMC Pharmaceuticals, Inc., Solon, OH; FluGen, Inc., Madison, WI; Foundry, Boston, MA; Nutrivert, Inc., Atlanta, GA; The United States Pharmacopeial Convention, Inc., Rockville, MD; Particella, Inc., San Francisco, CA; Ampulis, Inc., Berwyn, PA; Rozum Consulting, Newtown, PA; Halomine, Inc. dba AvantGuard, Ithaca, NY; Luminary Labs LLC, New York, NY; Pluri Biotech, Ltd., Haifa, STATE OF ISRAEL; Public Health Vaccines LLC, Cambridge, MA; B&S Research, Inc., Embarrass, MN; and General Therapeutics, Inc., Gaithersburg, MD have been added as parties to this venture.

Also, TFF Pharmaceuticals, Inc., Fort Worth, TX; Spring Discovery, Inc., San Carlos, CA; Cue Health, Inc., San Diego, CA; and Deimos Biosciences, San Francisco, CA have withdrawn as parties to this venture.

No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and RRPV intends to file additional written notifications disclosing all changes in membership.

On January 5, 2024, RRPV filed its original notification pursuant to section 6(a) of the Act. The Department of Justice published a notice in the **Federal Register** pursuant to section 6(b) of the Act on April 16, 2024 (89 FR 26928).

The last notification was filed with the Department on January 16, 2025. The Department of Justice published a notice in the **Federal Register** pursuant

to section 6(b) of the Act on February 28, 2025 (90 FR 10949).

Suzanne Morris,

*Deputy Director Civil Enforcement Operations, Antitrust Division.*

[FR Doc. 2025–10809 Filed 6–12–25; 8:45 am]

BILLING CODE P

## DEPARTMENT OF JUSTICE

### Antitrust Division

#### Notice Pursuant to the National Cooperative Research and Production Act of 1993—Subcutaneous Drug Development & Delivery Consortium, Inc.

Notice is hereby given that, on May 23, 2025, pursuant to section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* (“the Act”), Subcutaneous Drug Development & Delivery Consortium, Inc. (“Subcutaneous Drug Development & Delivery Consortium, Inc.”) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Matchstick LLC, Boonton, NJ; Gilead Sciences, Inc., Forest City, CA; SHL Medical AG, Zug, SWISS CONFEDERATION; and Regeneron Pharmaceuticals, Inc., Tarrytown, NY, have been added as parties to this venture.

No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and Subcutaneous Drug Development & Delivery Consortium, Inc. intends to file additional written notifications disclosing all changes in membership.

On October 26, 2020, Subcutaneous Drug Development & Delivery Consortium, Inc. filed its original notification pursuant to section 6(a) of the Act. The Department of Justice published a notice in the **Federal Register** pursuant to section 6(b) of the Act on December 3, 2020 (85 FR 78148).

The last notification was filed with the Department on October 4, 2024. A notice was published in the **Federal Register** pursuant to section 6(b) of the

Act on December 20, 2024 (89 FR 104209).

Suzanne Morris,

*Deputy Director Civil Enforcement Operations, Antitrust Division.*

[FR Doc. 2025–10806 Filed 6–12–25; 8:45 am]

BILLING CODE P

## DEPARTMENT OF JUSTICE

### Antitrust Division

#### Notice Pursuant to the National Cooperative Research and Production Act of 1993—Electrified Vehicle and Energy Storage Evaluation—II

Notice is hereby given that, on April 3, 2025, pursuant to section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* (“the Act”), Electrified Vehicle and Energy Storage Evaluation—II (“EVESE II”) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing (1) the identities of the parties to the venture and (2) the nature and objectives of the venture. The notifications were filed for the purpose of invoking the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances.

Pursuant to section 6(b) of the Act, the identities of the parties to the venture are: BAE Systems Controls Inc., Endicott, NY; Castrol Limited, Reading, UNITED KINGDOM; Ford Motor Company, Dearborn, MI; Honda Development & Manufacturing of America, LLC, Marysville, OH; and Komatsu America Corp, Chicago, IL. The general area of EVESE II’s planned activities are to develop enhanced understanding of battery energy storage systems for both vehicular and non-vehicular applications. Research considers both normal (cycling) and abnormal (abuse) use cases of lithium-ion batteries, and work will be performed in three broad areas: cell, module and applications.

Suzanne Morris,

*Deputy Director Civil Enforcement Operations, Antitrust Division.*

[FR Doc. 2025–10774 Filed 6–12–25; 8:45 am]

BILLING CODE P

## DEPARTMENT OF JUSTICE

### Antitrust Division

#### Notice Pursuant to the National Cooperative Research and Production Act of 1993—Global Synchronizer Foundation

Notice is hereby given that, on May 19, 2025, pursuant to section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* (“the Act”), Global Synchronizer Foundation (“GSF”) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Proof Group, Menlo Park, CA; T-RIZE Group, Montreal, CANADA; Chainlink Labs, New York, NY; and BNP Paribas, Paris, FRENCH REPUBLIC, have been added as parties to this venture.

No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and GSF intends to file additional written notifications disclosing all changes in membership.

On September 18, 2024, GSF filed its original notification pursuant to section 6(a) of the Act. The Department of Justice published a notice in the **Federal Register** pursuant to section 6(b) of the Act on October 11, 2024 (89 FR 82632).

The last notification was filed with the Department on February 25, 2025. A notice was published in the **Federal Register** pursuant to section 6(b) of the Act on March 7, 2025 (90 FR 11553).

Suzanne Morris,

*Deputy Director Civil Enforcement Operations, Antitrust Division.*

[FR Doc. 2025–10776 Filed 6–12–25; 8:45 am]

BILLING CODE P

## DEPARTMENT OF JUSTICE

### Antitrust Division

#### Notice Pursuant to the National Cooperative Research and Production Act of 1993—National Fire Protection Association

Notice is hereby given that, on May 1, 2025, pursuant to section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* (“the Act”), National Fire Protection Association (“NFPA”) has filed written notifications